Pascal O Bessong1, Nontokozo D Matume2, Denis M Tebit2,3. 1. AIDS Virus Research Laboratory, HIV/AIDS and Global Health Research Programme, University of Venda, Thohoyandou, 0950, South Africa. bessong@univen.ac.za. 2. AIDS Virus Research Laboratory, HIV/AIDS and Global Health Research Programme, University of Venda, Thohoyandou, 0950, South Africa. 3. Global Biomed Scientific LLC, P.O. Box 2368, Forest, VA, 24551, USA.
Abstract
BACKGROUND: South Africa, with one of the highest HIV prevalences in the world, introduced the universal test and treat (UTT) programme in September 2016. Barriers to sustained viral suppression may include drug resistance in the pre-treated population, non-adherence, acquired resistance; pharmacokinetics and pharmacodynamics, and concurrent use of alternative treatments. OBJECTIVE: The purpose of this review is to highlight potential challenges to achieving sustained viral load suppression in South Africa (SA), a major expectation of the UTT initiative. METHODOLOGY: Through the PRISMA approach, published articles from South Africa on transmitted drug resistance; adherence to ARV; host genetic factors in drug pharmacokinetics and pharmacodynamics, and interactions between ARV and herbal medicine were searched and reviewed. RESULTS: The level of drug resistance in the pre-treated population in South Africa has increased over the years, although it is heterogeneous across and within Provinces. At least one study has documented a pre-treated population with moderate (> 5%) or high (> 15%) levels of drug resistance in eight of the nine Provinces. The concurrent use of ARV and medicinal herbal preparation is fairly common in SA, and may be impacting negatively on adherence to ARV. Only few studies have investigated the association between the genetically diverse South African population and pharmacokinetics and pharmacodynamics of ARVs. CONCLUSION: The increasing levels of drug resistant viruses in the pre-treated population poses a threat to viral load suppression and the sustainability of first line regimens. Drug resistance surveillance systems to track the emergence of resistant viruses, study the burden of prior exposure to ARV and the parallel use of alternative medicines, with the goal of minimizing resistance development and virologic failure are proposed for all the Provinces of South Africa. Optimal management of the different drivers of drug resistance in the pre-treated population, non-adherence, and acquired drug resistance will be beneficial in ensuring sustained viral suppression in at least 90% of those on treatment, a key component of the 90-90-90 strategy.
BACKGROUND:South Africa, with one of the highest HIV prevalences in the world, introduced the universal test and treat (UTT) programme in September 2016. Barriers to sustained viral suppression may include drug resistance in the pre-treated population, non-adherence, acquired resistance; pharmacokinetics and pharmacodynamics, and concurrent use of alternative treatments. OBJECTIVE: The purpose of this review is to highlight potential challenges to achieving sustained viral load suppression in South Africa (SA), a major expectation of the UTT initiative. METHODOLOGY: Through the PRISMA approach, published articles from South Africa on transmitted drug resistance; adherence to ARV; host genetic factors in drug pharmacokinetics and pharmacodynamics, and interactions between ARV and herbal medicine were searched and reviewed. RESULTS: The level of drug resistance in the pre-treated population in South Africa has increased over the years, although it is heterogeneous across and within Provinces. At least one study has documented a pre-treated population with moderate (> 5%) or high (> 15%) levels of drug resistance in eight of the nine Provinces. The concurrent use of ARV and medicinal herbal preparation is fairly common in SA, and may be impacting negatively on adherence to ARV. Only few studies have investigated the association between the genetically diverse South African population and pharmacokinetics and pharmacodynamics of ARVs. CONCLUSION: The increasing levels of drug resistant viruses in the pre-treated population poses a threat to viral load suppression and the sustainability of first line regimens. Drug resistance surveillance systems to track the emergence of resistant viruses, study the burden of prior exposure to ARV and the parallel use of alternative medicines, with the goal of minimizing resistance development and virologic failure are proposed for all the Provinces of South Africa. Optimal management of the different drivers of drug resistance in the pre-treated population, non-adherence, and acquired drug resistance will be beneficial in ensuring sustained viral suppression in at least 90% of those on treatment, a key component of the 90-90-90 strategy.
Entities:
Keywords:
Potential challenges; South Africa; Treatment outcomes; Universal test and treat; Viral suppression
Authors: G M Hunt; J Ledwaba; A E Basson; J Moyes; C Cohen; B Singh; S Bertagnolio; M R Jordan; A Puren; L Morris Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Neil A Martinson; Lynn Morris; Jeffrey Johnson; Glenda E Gray; Visva Pillay; Johanna Ledwaba; Puleng Dhlamini; Sarah Cohen; Adrian Puren; Jan Steyn; Walid Heneine; James A McIntyre Journal: AIDS Date: 2009-04-27 Impact factor: 4.177
Authors: Kuan-Hsiang Gary Huang; Dominique Goedhals; Helen Fryer; Cloete van Vuuren; Aris Katzourakis; Tulio De Oliveira; Helen Brown; Sharon Cassol; Chris Seebregts; Angela McLean; Paul Klenerman; Rodney Phillips; John Frater Journal: Antivir Ther Date: 2009
Authors: Christopher J Hoffmann; Salome Charalambous; John Sim; Joanna Ledwaba; Graham Schwikkard; Richard E Chaisson; Katherine L Fielding; Gavin J Churchyard; Lynn Morris; Alison D Grant Journal: Clin Infect Dis Date: 2009-12-15 Impact factor: 9.079
Authors: Lynn T Matthews; Catherine Orrell; Mwebesa Bosco Bwana; Alexander C Tsai; Christina Psaros; Stephen Asiimwe; Gideon Amanyire; Nicholas Musinguzi; Kathleen Bell; David R Bangsberg; Jessica E Haberer Journal: J Int AIDS Soc Date: 2020-08 Impact factor: 5.396
Authors: James R Hargreaves; Triantafyllos Pliakas; Graeme Hoddinott; Tila Mainga; Constance Mubekapi-Musadaidzwa; Deborah Donnell; Ethan Wilson; Estelle Piwowar-Manning; Yaw Agyei; Nomtha F Bell-Mandla; Rory Dunbar; Ab Schaap; David Macleod; Sian Floyd; Peter Bock; Sarah Fidler; Janet Seeley; Anne Stangl; Virginia Bond; Helen Ayles; Richard J Hayes Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707
Authors: Adenike O Soogun; Ayesha B M Kharsany; Temesgen Zewotir; Delia North; Ebenezer Ogunsakin; Perry Rakgoale Journal: Trop Med Infect Dis Date: 2022-09-06
Authors: Lufuno G Mavhandu-Ramarumo; Lisa A M Tambe; Nontokozo D Matume; David Katerere; Pascal O Bessong Journal: South Afr J HIV Med Date: 2021-04-08 Impact factor: 2.744
Authors: Tafadzwa Dzinamarira; Solomon Mukwenha; Zindoga Mukandavire; Diego F Cuadros; Grant Murewanhema; Roda Madziva; Godfrey Musuka Journal: Lancet Glob Health Date: 2021-10-22 Impact factor: 26.763